<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="HE26219CF0EE84984AE29BC2B7B7BEBE9" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>118 HR 5850 IH: To nullify modifications made by the Food and Drug Administration on January 3, 2023, to the risk evaluation and mitigation strategy under section 505–1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355–1) for mifepristone, and for other purposes.</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2023-09-29</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">118th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 5850</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20230929">September 29, 2023</action-date><action-desc><sponsor name-id="M000871">Mr. Mann</sponsor> (for himself and <cosponsor name-id="M001194">Mr. Moolenaar</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To nullify modifications made by the Food and Drug Administration on January 3, 2023, to the risk evaluation and mitigation strategy under section 505&#8211;1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355&#8211;1) for mifepristone, and for other purposes.</official-title></form><legis-body id="H1CD5A4DD1C5E40DDA445D55A5A3D3B83" style="OLC"> 
<section id="H557F914ACA354C97A9139E0C35F40731" section-type="section-one"><enum>1.</enum><header>Nullification of REMS modifications for mifepristone; no Federal funding to implement REMS for mifepristone</header> 
<subsection id="HB668E4D974544EE29BEEE1C0C742B1A4"><enum>(a)</enum><header>In general</header><text>The modifications made by the Food and Drug Administration on January 3, 2023, to the risk evaluation and mitigation strategy under section 505–1 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355-1">21 U.S.C. 355–1</external-xref>) for mifepristone are hereby nullified.</text></subsection> <subsection id="H867D27995B3742918C7F2BD90450E21E"><enum>(b)</enum><header>Prohibition on federal funds</header><text>No Federal funds may be used to establish, implement, or enforce—</text> 
<paragraph id="HCCE3FDE741D34CBE822A45CF4DE2D95B"><enum>(1)</enum><text>any provision of a risk evaluation and mitigation strategy under section 505–1 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355-1">21 U.S.C. 355–1</external-xref>) for mifepristone that is substantially similar to any of the modifications nullified by subsection (a); or</text></paragraph> <paragraph id="HB725B5EB31EC4AF0A7A7B4EE220AA9E6"><enum>(2)</enum><text>any non-enforcement or enforcement discretion policy for any provision of a risk evaluation and mitigation strategy under such section for mifepristone.</text></paragraph></subsection></section> 
</legis-body></bill>

